Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07229313
PHASE1

A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

Sponsor: Kivu Bioscience Inc.

View on ClinicalTrials.gov

Summary

This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.

Official title: A Phase 1 Dose-Finding and Dose-Expansion Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

76

Start Date

2025-11-13

Completion Date

2030-03-31

Last Updated

2026-03-10

Healthy Volunteers

No

Interventions

DRUG

KIVU-107

KIVU-107 will be administered IV.

Locations (4)

Kivu Trial Site

Sydney, New South Wales, Australia

Kivu Trial Site

Brisbane, Queensland, Australia

Kivu Trial Site

Adelaide, South Australia, Australia

Kivu Trial Site

Geelong, Victoria, Australia